Skip to content

dr. Van Oyen Peter

Urologie
contactgegevens
05/01/2018
Oncologisch Centrum

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12. PMID: 29431193dr. Brouwers Barbaradr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
06/12/2023
Urologie

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Genome Medicine; 2018 Nov 16;:1–13.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
09/12/2018
Urologie

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

Clinical Cancer Research. 2018 Sep 12;clincanres.1943.2018.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
05/01/2018
Urologie

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

Prostate. 2018 May;78(6):435–45.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
06/12/2023
Urologie

Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

Journal of Clinical Oncology. American Society of Clinical Oncology; 2017 May 20;35(15_suppl):5049–9.dr. Bols Alaindr. Van Oyen Peterdr. Ampe Jozefdr. Ghysel Christophe
Geen publicaties gevonden...